Literature DB >> 17951526

Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2.

Grazia Maria Spaggiari1, Andrea Capobianco, Heba Abdelrazik, Flavio Becchetti, Maria Cristina Mingari, Lorenzo Moretta.   

Abstract

Recently, a number of clinical trials used either mesenchymal stem cells (MSCs) or natural killer (NK) cells in an attempt to improve the effectiveness of hematopoietic stem cell transplantation (HSCT). In view of the relevant role of both MSCs and NK cells in HSCT, we have recently explored the result of possible interactions between the 2 cell types. We found that activated NK cells could kill MSCs, whereas MSCs strongly inhibited interleukin-2 (IL-2)-induced NK-cell proliferation. In this study, we further analyzed the inhibitory effect exerted by MSCs on NK cells. We show that MSCs not only inhibit the cytokine-induced proliferation of freshly isolated NK cells but also prevent the induction of effector functions, such as cytotoxic activity and cytokine production. Moreover, we show that this inhibitory effect is related to a sharp down-regulation of the surface expression of the activating NK receptors NKp30, NKp44, and NKG2D. Finally, we demonstrate that indoleamine 2,3-dioxygenase and prostaglandin E2 represent key mediators of the MSC-induced inhibition of NK cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17951526     DOI: 10.1182/blood-2007-02-074997

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  409 in total

1.  Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease.

Authors:  M Youd; C Blickarz; L Woodworth; T Touzjian; A Edling; J Tedstone; M Ruzek; R Tubo; J Kaplan; T Lodie
Journal:  Clin Exp Immunol       Date:  2010-04-29       Impact factor: 4.330

Review 2.  Multipotent mesenchymal stromal cells and the innate immune system.

Authors:  Katarina Le Blanc; Dimitrios Mougiakakos
Journal:  Nat Rev Immunol       Date:  2012-04-25       Impact factor: 53.106

Review 3.  Recent progress toward understanding the physiological function of bone marrow mesenchymal stem cells.

Authors:  Chao Shi
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

Review 4.  Mesenchymal stem cells: Mechanisms of immunomodulation and homing.

Authors:  Hiroshi Yagi; Alejandro Soto-Gutierrez; Biju Parekkadan; Yuko Kitagawa; Ronald G Tompkins; Naoya Kobayashi; Martin L Yarmush
Journal:  Cell Transplant       Date:  2010-06-03       Impact factor: 4.064

Review 5.  The immunomodulatory properties of mesenchymal stem cells: implications for surgical disease.

Authors:  Brent R Weil; Mariuxi C Manukyan; Jeremy L Herrmann; Aaron M Abarbanell; Jeffrey A Poynter; Yue Wang; Daniel R Meldrum
Journal:  J Surg Res       Date:  2010-08-06       Impact factor: 2.192

Review 6.  Emerging therapeutic approaches for multipotent mesenchymal stromal cells.

Authors:  Paolo F Caimi; Jane Reese; Zhenghong Lee; Hillard M Lazarus
Journal:  Curr Opin Hematol       Date:  2010-11       Impact factor: 3.284

Review 7.  Activity of mesenchymal stem cells in therapies for chronic skin wound healing.

Authors:  Austin Nuschke
Journal:  Organogenesis       Date:  2013-12-10       Impact factor: 2.500

8.  Distinct Immunoregulatory Mechanisms in Mesenchymal Stem Cells: Role of the Cytokine Environment.

Authors:  Vladimir Holan; Barbora Hermankova; Pavla Bohacova; Jan Kossl; Milada Chudickova; Michaela Hajkova; Magdalena Krulova; Alena Zajicova; Eliska Javorkova
Journal:  Stem Cell Rev Rep       Date:  2016-12       Impact factor: 5.739

9.  Flk-1+ mesenchymal stem cells aggravate collagen-induced arthritis by up-regulating interleukin-6.

Authors:  B Chen; J Hu; L Liao; Z Sun; Q Han; Z Song; R C Zhao
Journal:  Clin Exp Immunol       Date:  2009-12-04       Impact factor: 4.330

10.  Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?

Authors:  Timothy E Krueger; Daniel L J Thorek; Alan K Meeker; John T Isaacs; W Nathaniel Brennen
Journal:  Prostate       Date:  2018-11-28       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.